Astellas Pharma Inc. Sees U.S. Delay on Transplant Drug Advagraf

March 14, 2008 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

TOKYO (Reuters) - Japan's Astellas Pharma Inc said on Friday that U.S. authorities have requested more information on its key kidney transplant drug Advagraf, meaning it will face further delays in receiving approval there.

Twitter
LinkedIn
Facebook
Email
Print

Regulatory Asia

Astellas Pharma US, Inc.